{"id":46446,"date":"2026-03-23T14:32:12","date_gmt":"2026-03-23T14:32:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/46446\/"},"modified":"2026-03-23T14:32:12","modified_gmt":"2026-03-23T14:32:12","slug":"novo-nordisk-advances-obesity-pipeline-with-early-stage-oral-drug-trial-from-lexicon-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/46446\/","title":{"rendered":"Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal"},"content":{"rendered":"<p>The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and commercialize the drug.<\/p>\n<p>Novo Nordisk (NVO) is pushing deeper into next-gen obesity treatments. The drugmaker announced on Monday that it has initiated a Phase 1 study of LX9851, Lexicon Pharmaceuticals\u2019 oral non-incretin drug candidate for obesity and related metabolic disorders.\u00a0<\/p>\n<p>This adds to Novo\u2019s obesity treatment pipeline, which also features the semaglutide injection, famously known as Wegovy.\u00a0<\/p>\n<p>At the time of writing, <a href=\"https:\/\/stocktwits.com\/symbol\/NVO\" rel=\"nofollow noopener\" target=\"_blank\">NVO shares<\/a> fell 1.5%, while <a href=\"https:\/\/stocktwits.com\/symbol\/LXRX\" rel=\"nofollow noopener\" target=\"_blank\">Lexicon Pharmaceuticals\u2019<\/a> (LXRX) stock climbed around 1% in Monday pre-market trading.<\/p>\n<p>The start of the trial triggered a second $10 million milestone payment to Lexicon under their licensing deal signed in March 2025. The agreement gives Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible to receive up to $1 billion in total milestone payments, as well as royalties on future sales.<\/p>\n<p>The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants. The trial is expected to be completed in early 2027, marking an important step in advancing the company\u2019s pipeline.<\/p>\n<p>\u201cLX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities,\u201d said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk.\u00a0<\/p>\n<p>Get updates to this developing story on Stocktwits.<\/p>\n<p>For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n<p><a class=\"STButton_lg__XBy4m text-lg px-6 gap-2 STButton_button__ObG_J h-[--size] inline-flex flex-row items-center justify-center border rounded-full font-semibold whitespace-nowrap STButton_black-secondary__xIxs1 bg-white text-black border-secondary-button-border dark|bg-transparent dark|text-white hover|!bg-light-grey-6 dark|hover|!bg-dark-grey-5 p-2\" role=\"button\" tabindex=\"0\" type=\"button\" target=\"_blank\" rel=\"noopener nofollow\" href=\"https:\/\/news.google.com\/publications\/CAAqKQgKIiNDQklTRkFnTWFoQUtEbk4wYjJOcmRIZHBkSE11WTI5dEtBQVAB\"><img decoding=\"async\" alt=\"Follow on Google News\" src=\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/><\/a><\/p>\n<p>Subscribe to Chart Art<\/p>\n<p>The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.<\/p>\n<p><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.stocktwits.com\/about-newsroom\/\" class=\"NewsArticle_editorialLink__1BMFs hover|text-blue-ada underline w-full text-base\">Read about our editorial guidelines and ethics policy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and&hellip;\n","protected":false},"author":2,"featured_media":12182,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[26295,272,26294,26296,7977,26297],"class_list":{"0":"post-46446","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-lexicon-lx9851","9":"tag-novo-nordisk","10":"tag-novo-nordisk-lexicon-partnership","11":"tag-novo-phase-1-lx9851","12":"tag-nvo-shares","13":"tag-us-premarket"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116278981105836302","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/46446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=46446"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/46446\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/12182"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=46446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=46446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=46446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}